 Scaling The Peaks Biotech Stocks Hitting 52-week Highs Aug. 12 Annexon Inc NASDAQ: ANNX Cellular Biomedicine Group Inc NASDAQ: CBMG announced a go-private deal Fulgent Genetics Inc NASDAQ: FLGT Inari Medical Inc NASDAQ: NARI iTeos Therapeutics Inc NASDAQ: ITOS Orthopediatrics Corp NASDAQ: KIDS Penumbra Inc NYSE: PEN Shockwave Medical Inc NASDAQ: SWAV reacted to second-quarter resultsDown In The Dumps Biotech Stocks Hitting 52-week Lows Aug. 12 Burning Rock Biotech Ltd NASDAQ: BNR Checkmate Pharmaceuticals Inc NASDAQ: CMPI went public Friday Entera Bio Ltd NASDAQ: ENTX Eyepoint Pharmaceuticals Inc NASDAQ: EYPT Iterum Therapeutics PLC NASDAQ: ITRM announced commencement of a rights offering Lantern Pharma Inc. NASDAQ: LTRN Legend Biotech Corp NASDAQ: LEGN Poseida Therapeutics, Inc. NASDAQ: PSTX Recro Pharma Inc NASDAQ: REPH Verrica Pharmaceuticals Inc NASDAQ: VRCAStocks In Focus Novartis Files For Label Expansion For Self-Administered Allergic Asthma Drug Novartis AG NYSE: NVS said the FDA accepted the sBLA for a self-administration option for Xolair across all approved U.S. indications. If approved, Xolair pre-filled syringes would become available for either self-administration by select patients or administration by their caregivers, the company said.A decision on approval is expected in the first quarter of 2021, Novartis said.Xolair is approved for treating patients with moderate to severe persistent allergic asthma and chronic idiopathic urticaria.The stock was edging up 0.88 to 85.68 in premarket trading Thursday.Sorrento Denies Allegations By Hindenburg Regarding COVID-19 Diagnostic Test Pushing back against allegations by Hindenburg Research, Sorrento Therapeutics Inc NASDAQ: SRNE said a report published by the short seller regarding its COVID-19 diagnostic spit test includes false andor misleading statements for the sole apparent purpose of negatively manipulating the companys stock price.The company said in a press release that it has demanded through its counsel that Hindenburg cease and desist from illegal and wrongful activity and retract false andor misleading statements. It also said it is contemplating legal action.The stock was advancing 9.19 to 13.55 in premarket trading Thursday.Heat Biologics Reports Positive Preclinical Results For COVID-19 Vaccine Candidate Heat Biologics Inc NASDAQ: HTBX reported preclinical data for its gp96-based COVID-19 vaccine candidate showing robust T-cell mediated immune response directed against the spike protein of SARS-CoV-2.The data was generated at the University of Miami Miller School of Medicine.The stock was jumping 24.36 to 1.94 in premarket trading Thursday.See also: The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earning BioCryst CFO Buys Shares BioCryst Pharmaceuticals, Inc. NASDAQ: BCRX shares reacted to a Form 4 filing by the company with the SEC regarding purchase of 54,000 of its shares by CFO Doyle Anthony.View more earnings on IBBThe stock was up 5.29 to 4.18 premarket Thursday.Earnings Brickell Biotech Inc NASDAQ: BBI said its second-quarter revenue fell from 2.6 million in 2019 to 600,000 in 2020. The loss per share narrowed from 6.48 to 43 cents.The stock was moving down 4.39 to 85 cents in premarket trading Thursday.Biocept Incs NASDAQ: BIOC second-quarter revenue declined from 1.2 million in 2019 to 917,000 in 2020. The net loss per share narrowed from 38 cents to 5 cents and was in line with estimates.In premarket trading Thursday, the stock was trading 0.98 higher at 1.03. Eyenovia Inc NASDAQ: EYEN said its net loss per share narrowed from 44 cents to 25 cents, with the loss per share coming in line with expectations.The stock was moving down 6.86 to 4.75 in premarket trading Thursday.Cyclacel Pharmaceuticals Inc NASDAQ: CYCC reported a loss of 58 cents per share, narrower than the year-ago loss of 2.13 per share but wider than the consensus loss estimate of 47 cents per share.The stock was shedding 6.36 to 4.27 in premarket trading Thursday.On The Radar Adcom Meeting FDAs Oncology Drug Advisory Committee will discuss Thursday Mesoblast limiteds NASDAQ: MESO BLA for remestemcel-L for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. Briefing document released ahead of the meeting showed FDA staffers werent convinced regarding the efficacy of the investigational therapy.Earnings RedHill Biopharma Ltd NASDAQ: RDHL before the market open Vascular Biogenics Ltd NASDAQ: VBLT before the market open PDS Biotechnology Corp NASDAQ: PDSB before the market open Zai Lab Ltd NASDAQ: ZLAB before the market open Veru Inc NASDAQ: VERU before the market open aTyr Pharma Inc NASDAQ: LIFE after the market close Caladrius Biosciences Inc NASDAQ: CLBS after the market close Dyadic International, Inc. NASDAQ: DYAI after the market close Myriad Genetics, Inc. NASDAQ: MYGN after the market close Histogen Inc NASDAQ: HSTO after the market close Lumos Pharma Inc NASDAQ: LUMO after the market close Viveve Medical Inc NASDAQ: VIVE after the market close Urovant Sciences Ltd NASDAQ: UROV after the market close Aptinyx Inc NASDAQ: APTX after the market close Navidea Biopharmaceuticals Inc NYSE: NAVB after the market close Reshape Lifesciences Inc OTC: RSLS after the market closeRelated Link: Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates See more from BenzingaC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 